Author

F. Ciceri

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Organism:mouse· 1

Frequent Co-Authors

A. Conti· 1 shared A. Curti· 1 shared A. Gulino· 1 shared A. Piva· 1 shared A. Santoro· 1 shared A. Tzankov· 1 shared B. Bassani· 1 shared C. A. Schmitt· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Conti

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ZEB1 shapes AML immunological niches suppressing CD8 T-cell activity while fostering Th17 cell expansion.

B. Bassani, G. Simonetti, V. Cancila, M. Ciciarello, A. Piva, C. Chiodoni, D. Lecis, A. Gulino, E. Fonzi, L. Botti, P. Portararo, M. Costanza, J. Schwaller, A. Tzankov, M. Ponzoni, , S. Sangaletti

This study shows ZEB1 in AML suppresses CD8 T-cells and promotes Th17 cells, contributing to immune suppression and tumor progression.

bioRxiv · Jul 8, 2023Immunology

Therapy-induced senescence upregulates antigen presentation machinery and triggers anti-tumor immunity in Acute Myeloid Leukemia

D. Gilioli, S. Fusco, T. Tavella, K. Giannetti, A. Conti, A. Santoro, E. Carsana, S. Beretta, M. Schonlein, V. Gambacorta, F. M. Aletti, M. G. Carraba, C. Bonini, F. Ciceri, I. Merelli, , R. Di Micco

This study shows therapy-induced senescence in AML upregulates antigen presentation and enhances T-cell anti-leukemic activity, suggesting senescence as a target for immunotherapy.

bioRxiv · Nov 17, 2022 · PreprintCancer Biology